宝莫股份(002476) - 2024 Q4 - 年度财报

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2024, representing a year-on-year increase of 15%[12]. - The company's operating revenue for 2024 reached ¥538,662,863.81, representing a 39.07% increase compared to ¥387,338,190.19 in 2023[18]. - Net profit attributable to shareholders surged to ¥56,393,834.63 in 2024, a remarkable increase of 977.59% from ¥5,233,314.15 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥4,184,005.19, showing a 123.74% improvement from a loss of ¥17,627,081.37 in 2023[18]. - Basic and diluted earnings per share increased to ¥0.0921, up 970.93% from ¥0.0086 in 2023[18]. - Total assets at the end of 2024 were ¥1,050,934,577.54, a 9.00% increase from ¥964,151,009.85 at the end of 2023[18]. - The net assets attributable to shareholders rose to ¥926,981,167.08, reflecting a 5.69% increase from ¥877,057,141.10 in 2023[18]. - Investment income surged to ¥44,547,370.56, a remarkable increase of 3459.48% year-on-year, primarily due to the termination of equity investment in Risheng Mining by the wholly-owned subsidiary Chengdu Baomo[36]. - The company's total expenses for the reporting period were ¥73,456,973.85, a decrease of 7.21% compared to the previous year[36]. - The company reported a credit impairment loss of -¥12,336,990.47, a significant reduction of 396.65% year-on-year, due to increased provisions for credit impairment losses[36]. Dividend Distribution - The company plans to distribute a cash dividend of 0.1 RMB per 10 shares to all shareholders, based on a total of 612,000,000 shares[5]. - The cash dividend distribution plan is compliant with the company's articles of association and shareholder resolutions[116]. - The net profit attributable to shareholders for the year 2024 is 56,393,834.63 RMB, with cumulative undistributed profits of 83,220,873.27 RMB as of December 31, 2024[118]. Operational Developments - The company is focusing on expanding its market presence and is exploring new product development initiatives[12]. - The company has established long-term framework agreements with key suppliers for raw material procurement, ensuring stable supply[27]. - The company has developed a microbial method for producing acrylamide, achieving international leading production technology[31]. - The company has a strong R&D team focused on continuous improvement of production processes to meet downstream customer demands[31]. - The company is focusing on enhancing innovation capabilities and improving operational efficiency through various measures, including optimizing production processes and developing new products[28]. Risk Management - The company has outlined potential risks in its operations, which are detailed in the management discussion and analysis section of the report[5]. - The company faces risks related to oil price fluctuations, high customer concentration, and raw material price volatility, which could impact its financial performance[74]. Corporate Governance - The company is committed to improving corporate governance and transparency, ensuring timely and accurate disclosure of its operational status to enhance investor confidence[73]. - The company has established specialized committees within the board to promote standardized operations and sustainable development[79]. - The board of directors and supervisory board operate independently, with no significant discrepancies from the regulations set by the China Securities Regulatory Commission[82]. - The company has implemented effective internal control measures to enhance management efficiency and risk prevention capabilities[81]. Environmental Compliance - The company holds a pollution discharge permit valid from February 19, 2024, to February 18, 2029[128]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[127]. - The company adheres to multiple environmental laws and standards, including the Water Pollution Prevention Law and the Air Pollution Prevention Law[127]. - The company has implemented a comprehensive environmental management system to reduce operational impacts on the environment and promote resource recycling[142]. Human Resources - The company has implemented a training plan focusing on safety production education, quality management, and skill enhancement for employees[113]. - The total number of employees at the end of the reporting period is 428, with 422 from major subsidiaries and 6 from the parent company[110]. - The professional composition includes 244 production personnel, 24 sales personnel, 104 technical personnel, 13 financial personnel, and 43 administrative personnel[111]. Shareholder Engagement - The company held two annual shareholder meetings in 2024, with the first on May 22, 2024, discussing 12 proposals, and the second on July 23, 2024, addressing 13 proposals related to issuing shares to specific targets[79]. - The company maintained a 16.11% investor participation rate at the 2023 annual shareholder meeting and a 23.04% participation rate at the first temporary shareholder meeting in 2024[85]. - The company actively maintains communication with investors through various platforms to ensure timely and accurate information disclosure[141]. Leadership Changes - The company announced a leadership change with the appointment of Li Ding as the new General Manager, effective May 22, 2024, following the departure of Tao Xucheng[89]. - Financial Director Wen Li has been appointed, replacing Wang Shuyi, effective May 22, 2024[89]. - The company is preparing for a new round of board and management elections, which may influence future strategic directions[88]. Legal Matters - The company filed a lawsuit against Xian Dao Pharmaceutical for breach of contract, which was accepted by the court in April 2023, with a hearing held on August 10, 2023[175]. - On August 23, 2023, the company received a civil judgment from the court, and subsequently applied for enforcement due to Xian Dao Pharmaceutical's failure to fulfill obligations[175]. - The company signed a share transfer agreement with Xian Dao Pharmaceutical in March 2022, agreeing to transfer 30% equity of Lida Pharmaceutical for RMB 13 million[174].